Trials / Completed
CompletedNCT03630562
Assay of Pro-angiogenic Cytokines in Exudative Age-Related Macular Degeneration
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 100 (actual)
- Sponsor
- Centre Hospitalier Universitaire de Nice · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Anti-VEGF intravitreal injections are the treatment of choice in age-related macular degeneration (AMD). However 37% of patients are unresponsive or poorly responsive to these therapies. It is still not possible to foresee the patient's response to anti-VEGF injections. A poor response may be related to an activation of alternative pro-angiogenic pathways with over expression of many other pro-angiogenic cytokines. The primary goal of this study is to measure the aqueous humor concentration of pro-angiogenic cytokines in AMD patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Aqueous humor samples collection | In addition to the routine examinations performed as part of the usual care of AMD patients, an anterior chamber puncture will be performed to collect the aqueous humor samples. |
Timeline
- Start date
- 2018-11-26
- Primary completion
- 2021-01-12
- Completion
- 2021-08-19
- First posted
- 2018-08-15
- Last updated
- 2026-03-24
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT03630562. Inclusion in this directory is not an endorsement.